Research Purpose: GLUT1 deficiency syndrome (GLUT1DS) is a rare genetic disorder caused by a mutation in the SLC2A1 gene that limits the transport of glucose across the blood-brain barrier. Speech disorders and dysarthria are typical findings in patients with GLUT1DS, but have never been deeply phenotyped. The aim of the present study was to characterize speech abilities in a sample of patients with GLUT1DS.
Results: 30 patients with GLUT1DS were recruited. We reported impairments in different speech and oromotor domains: the speech was characterized by dysarthria, inaccurate articulation of consonants, abnormal nasal resonance, errors in intonation and prosody and low intelligibility. We observed difficulties in motor planning and programming. Moreover, we observed a significant difference between the dysarthric level of impairment with genotype groups.
Conclusions: The presence of a speech disorder in patients with GLUT1DS represents a core feature of the syndrome. Our findings suggest that patients with GLUT1DS would benefit from a comprehensive neurocognitive assessment to detect strengths and weaknesses of the speech profile. Understanding the speech and language phenotype in GLUT1DS is critical for planning early intervention to positively influence the global development of patients with GLUT1DS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejpn.2024.05.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring ketogenic diet resistance in glucose transporter type 1 deficiency syndrome: A comprehensive review and critical appraisal.
Epilepsia Open
December 2024
Department of Neuropediatrics, University Children's Hospital Zurich, Zurich, Switzerland.
Glucose transporter type 1 deficiency syndrome (GLUT1DS) commonly presents with early-onset epilepsy that often resists conventional pharmacological treatment. Ketogenic diet therapy (KDT) is the preferred approach to address the underlying metabolic anomaly. However, a subset of GLUT1DS patients presents resistance to KDT, with the causes remaining elusive.
View Article and Find Full Text PDFEpileptiform activity in brain organoids derived from patient with Glucose Transporter 1 Deficiency Syndrome.
Front Neurosci
November 2024
GliaPharm SA, Geneva, Switzerland.
Introduction: Glucose Transporter 1-Deficiency Syndrome (GLUT1-DS) is a rare genetic disorder caused by mutations in the gene encoding for GLUT1 and characterized by impaired glucose uptake in the brain. This leads to brain hypometabolism and the development of symptoms that include epilepsy, motor dysfunctions and cognitive impairment. The development of patient-specific models is a valuable tool for understanding the pathophysiology of rare genetic disorders and testing new therapeutic interventions.
View Article and Find Full Text PDFGeneration of human induced pluripotent stem cell lines derived from two glucose transporter 1 deficiency syndrome patients.
Stem Cell Res
December 2024
iPS Cell Advanced Characterization and Development Team, BioResource Research Center, RIKEN, 3-1-1 Koyadai, Tsukuba, Ibaraki 305-0074, Japan; School of Integrative and Global Majors, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8577, Japan. Electronic address:
Glucose transporter 1 deficiency syndrome (GLUT1DS), caused by impaired glucose transport at the blood-brain barriers, leads to various central nervous system dysfunctions. A comprehensive understanding of the underlying disease pathogenesis is still lacking. In this study, we have generated GLUT1DS-specific human induced pluripotent stem cells (hiPSCs) derived from two patients.
View Article and Find Full Text PDFClinical and genetic analysis of children with glucose transporter type 1 deficiency syndrome.
Med Int (Lond)
July 2024
Department of Neurology, Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu 210006, P.R. China.
Article Synopsis
- GLUT1 deficiency syndrome (GLUT1-DS) is a rare metabolic disorder that affects brain function, leading to various neurological symptoms such as convulsions and movement disorders.
- A study of 15 patients diagnosed with GLUT1-DS showed that all had significant symptoms but improved after following a ketogenic diet (KD) for up to a year, despite none having a typical cerebrospinal fluid glucose ratio.
- The study emphasized the importance of genetic testing, specifically for the solute carrier family 2 member 1 gene variant, as a diagnostic tool, and highlighted the KD as an effective treatment that can enhance the prognosis and quality of life for affected children.
Stroke and Stroke-Like Episodes: Recurrent Manifestations in GLUT1 Deficiency Syndrome.
Pediatr Neurol
August 2024
Pediatric Neurology Unit, Buzzi Children's Hospital, Milan, Italy; Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy. Electronic address:
Background: Since the initial description of glucose transporter-1 deficiency syndrome (Glut1-DS) the phenotype of the condition has expanded, even leading to the recognition of atypical manifestations. We report on eight patients with Glut1-DS who experienced at least one episode of acute focal neurological deficits.
Methods: We conducted a retrospective analysis, collecting clinical, electrophysiological, neuroradiological, and genetic information.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!